United Therapeutics (NASDAQ: UTHR) reported Q4 EPS of $4.36, $0.08 worse than the analyst estimate of $4.44. Revenue for the quarter came in at $614.7 million versus the consensus estimate of $575.1 million.

For earnings history and earnings-related data on United Therapeutics (UTHR) click here.